Analysis of Organisational Behaviour at Genzyme

Only available on StudyMode
  • Download(s) : 88
  • Published : April 29, 2013
Open Document
Text Preview
Analysis of Genzyme Waterford

Student Names: Fiona Mallon and Hazel Mc Partlan
Course: BA (Hons) in Marketing, Advertising and Online Media Module: Organisational Behaviour
Submission Date: 11th of April 2013
Word Count: 3218
Total Word Count: 7980
We declare that this work is our own and of the highest academic integrity. Where the work of others has been used, it is properly acknowledged and referenced

Table of Contents

1. Brief History of Genzyme3
2. Practice of Motivational Theories in Genzyme4
3. Managing Change in Genzyme7
4. Team Work Analysis9
5. References11
6. Appendices One; Interview Transcript13
7. Appendices Two; Progress Report One23
8. Appendices Three; Progress Report Two25
9. Appendices Four; Progress Report Three27

1. Brief History of Genzyme

The following is a brief description of Genzyme Corporation. This information provided, combined with the information gathered in the interview is to make and clear and precise report respectively. Genzyme is a biotechnology company, started in Cambridge, Massachusetts in 1981 by Sheridan Snyder, George M. Whitesides and scientist Henry Blair (Genzyme.com., 2013) From the offset the company was dedicated to finding cures for enzyme deficiency conditions that were essential for human survival. Genzyme is committed to discovering and delivering transformative therapies for patients with rare and special unmet medical needs, providing hope where there was none before. (Genzyme.com, 2013) From the beginning Genzyme has leveraged their expertise in many therapeutic areas and technology platforms to develop innovative, targeted answers to unmet medical needs worldwide. Although Genzyme aim to treat rare health deficiencies worldwide they have seven main areas in which they are dedicated to. Their primary focus is Genetic Disease, Neurologic Disease, Renal Disease, Orthopaedics, Cardiovascular, Neuroimmunology Disease, and Immune –Medicated disease. Genzyme carry out extensive research into all of these areas, their patient’s health and survival is at the forefront of their aims. Johanne Kaplan VP of Neuroimmunology for Genzyme shares ; “Many of us here at Genzyme can put faces to the diseases we are working on, for most of us, research is more than just an interesting job, it is a personal quest”. This statement is testament to Genzyme’s success on a global scale. In 2010 Genzyme was the world’s third largest biotechnology company, employing more than 11,000 people around the world, leading manufacturers of biotech and oral dose products. These products are manufactured and produced globally. The focus of this report will be on Genzyme, Waterford. Established in 2001 The Waterford Plant is based on a 37 acre site. This multiphase biopharmaceutical facility has a capital investment of €400 million and employs over 450 personnel (Genzyme.ie, 2013).Genzyme operates two manufacturing facilities, Oral Dosage and Fill Finish. After the construction phase of Genzyme was completed the first manufacturing facility to operate was Oral Dosage. This was tabletting suite for the packaging of Renagel; this suite has been supplying dialysis patients globally since 2003. The first fill finish manufacturing plant commenced commercial supply of thymoglobulin in 2006. Thymoglobulin is an immunosuppressant. It is used to reduce the natural immunity in patients who receive kidney transplants. The second Oral Dosage facility commenced operations in 2009, this enabled the global supply of Renvela, and the expansion enabled Genzyme to introduce a number of new products. An inclusive list of products sold to date are; Myozyme, Lumizyme, Cerezyme, Thymoglobulin, Cholestagel, Renvela and Renagel (Genzyme.com., 2013) In 2011 Genzyme Corporation was acquired by Global healthcare company Sanofi. By January 2012, the final stages of acquisition were completed in the U.K and Ireland. Although Genzyme were already large in respect they now make up...
tracking img